AbbVie Inc.

ABBV Healthcare & Pharma 5/10 Medium Risk
5/10

AbbVie Inc. has $64.5B in total long-term debt with $64.5B in scheduled maturities. Approximately $6.0B (9% of maturities) is due within the next twelve months, and operating income covers interest expense 5.7x. Overall, ABBV carries moderate refinancing risk (score 5/10).

Maturity Schedule

Year 1 $6.0B Year 2 $5.1B Year 3 $4.5B Year 4 $8.6B Year 5 $1.0B Beyond 5 $39.3B
Period Amount Due % of Total
Year 1 (0-12 months) $6.0B 9.3%
Year 2 (12-24 months) $5.1B 8.0%
Year 3 (24-36 months) $4.5B 6.9%
Year 4 (36-48 months) $8.6B 13.4%
Year 5 (48-60 months) $1.0B 1.6%
Beyond 5 Years $39.3B 60.9%
Total Scheduled Maturities $64.5B 100.0%

Key Metrics

Total Long-Term Debt
$64.5B
Near-Term (12mo)
$6.0B
Interest Coverage
5.7x
Debt/Equity
19.40
Cash Coverage
0.92x
Operating Income
$12.8B

Score Components

Component Value Weight
Near-Term Maturity Concentration 9.3% 30%
Interest Coverage Ratio 5.74x 25%
Debt-to-Equity Ratio 19.40 25%
Cash Coverage of Near-Term Debt 0.92x 20%

Related Companies

JOHNSON & JOHNSON
JNJ
1/10
Debt: $32.4B 12mo: $2.0B
PFIZER INC
PFE
5/10
Debt: $4.0B 12mo: N/A
Merck & Co., Inc.
MRK
3/10
Debt: N/A 12mo: $2.6B
ELI LILLY & Co
LLY
3/10
Debt: $19.1B 12mo: $781M
BRISTOL MYERS SQUIBB CO
BMY
4/10
Debt: $49.4B 12mo: $2.0B
AMGEN INC
AMGN
5/10
Debt: $60.1B 12mo: $4.6B
GILEAD SCIENCES, INC.
GILD
4/10
Debt: $26.7B 12mo: $2.8B
REGENERON PHARMACEUTICALS, INC.
REGN
1/10
Debt: N/A 12mo: N/A

Data Source: Financial data sourced from SEC EDGAR XBRL filings (10-K annual reports). Most recent filing date: 2026-02-20. Data last fetched: 2026-03-15. Maturity schedules reflect the company's most recently reported debt repayment obligations. Data quality: Complete.